This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

Exclusion Criteria

• •1.Fungal, bacterial, viral, or other infection not controlled and/or requiring hospitalization or intravenous antimicrobial therapy within 4 weeks prior to screening. Uncomplicated urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to current therapy;
• •2.Active tuberculosis or latent tuberculosis that has not been treated appropriately prior to screening;
• •3.History of severe hypersensitivity or allergy;
• •4.Primary immunodeficiency;
• •5.Impaired cardiac function or clinically significant cardiac disease;
• •6.History of serious respiratory diseases or current serious respiratory diseases, including moderate or severe or above asthma or chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis;
• •7.Current or history of cirrhosis;
• •8.History of Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus within the past 2 years, and the need for continuous use of systemic immunosuppressants/systemic disease-modifying drugs;
• •9.Any active malignancy or history of malignancy within 5 years prior to screening. The following are exceptions: early-stage tumors that have undergone radical treatment (carcinoma in situ or stage I tumors, non-ulcerative primary melanoma with a depth \< 1 mm and no lymph node involvement), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, thyroid carcinoma in situ or early-stage thyroid cancer that has undergone radical treatment, cervical carcinoma in situ, or breast cancer in situ that has undergone potentially radical treatment;
• •10.Those who have clinically significant bleeding symptoms or definite haemorrhagic diathesis within 6 months prior to screening;
• •11.Arterial or venous thrombotic events such as cerebrovascular disorders (including cerebral hemorrhage, cerebral infarction, etc), deep venous thrombosis, and/or pulmonary embolism within 6 months prior to screening;
• •12.Hematologic disorders: History of cytopenia consistent with myelodysplastic syndrome; history of sickle-cell anemia or other hemoglobinopathies;
• •13.Severe underlying medical conditions, such as:
• •1. Significant clinical evidence of dementia or mental status changes;
• •2. History of any other central nervous system (CNS) disorders or neurodegenerative diseases, such as epilepsy, seizure, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, and psychosis;
• •3. Mental disorders or psychosocial conditions that place patients at unacceptable risk.
• •14.Positive results in any of the following tests:
• •1. Positive for human immunodeficiency virus (HIV) antibody;
• •2. Positive for hepatitis B surface antigen (HBsAg); or positive for hepatitis B core antibody (HBcAb) with hepatitis B virus deoxyribonucleic acid (DNA) above the lower limit of detection of the assay;
• •3. Positive for hepatitis C virus (HCV) antibody with HCV ribonucleic acid (RNA) above the lower limit of detection of the assay;
• •4. Positive for antibodies against human T-cell lymphotropic virus types I and II;
• •5. Positive for syphilis antibody. As the immunosuppression included in this study may pose an unacceptable risk, those with active HIV infection, hepatitis B (positive for HBsAg), or HCV infection (positive for anti-HCV antibodies) are excluded. Subjects are allowed to have a previous history of hepatitis B or C, provided that viral load is shown to be below the limit of detection by quantitative polymerase chain reaction and/or nucleic acid testing. Hepatitis B surface antibodies produced following hepatitis B vaccination are not considered evidence of prior infection.
• •15.Administration of a live attenuated vaccine within 4 weeks prior to apheresis;
• •16.Receipt of a different investigational drug in a clinical trial within 4 weeks prior to apheresis, or the time interval from the last dose of the investigational drug in the previous drug clinical trial to the informed consent form (ICF) signing date is still within 5 half-lives of that drug (whichever is longer);
• •17.Splenectomy within 12 months prior to the signing of ICF;
• •18.Prior therapy targeting CD19 and/or BCMA, or CAR T product therapy against any target;
• •19.Receipt of rituximab within 6 months or ofatumumab within 4 months prior to apheresis;
• •20.Patients treated with siponimod and ozanimod within 1 month prior to apheresis;
• •21.Patients treated with fingolimod within 6 weeks prior to apheresis;
• •22.Patients treated with teriflunomide within 3 months prior to apheresis;
• •23.Major surgery within 8 weeks before the signing of ICF or planned surgery during the study (except for subjects scheduled for surgery under local anesthesia, provided that the surgery will not be performed within 2 weeks after infusion);
• •24.Previous history of organ transplantation;
• •25.Confirmed diagnosis of monophasic disease, radiologically isolated syndrome, clinically isolated syndrome, and progressive isolated sclerosis based on the 2017 McDonald criteria;
• •26.History of neuromyelitis optica spectrum disorder or myelin oligodendrocyte glycoprotein antibody-related disease, or neurological diseases suspected of MS at screening;
• •27.History of CNS or spinal cord tumors, metabolic or infectious spinal cord lesions, hereditary progressive CNS diseases, sarcoidosis, or non-MS progressive neurological diseases that interfere with study assessments;
• •28.CNS disorders, such as cerebrovascular ischemia/hemorrhage, dementia, previous or current spinal cord lesions, cerebellar diseases unrelated to MS, or other diseases deemed by the investigator to potentially interfere with neurotoxicity assessment;
• •29.History of seizures, even if seizures have been well controlled with antiepileptic drugs;
• •30.MS lesions or symptoms that have the potential to increase the risk of neurotoxicity, including but not limited to tumor-like lesions (≥ 3 cm in diameter within 5 years prior to screening) or depressed level of consciousness, and/or the presence of active, clinically significant concomitant CNS pathological changes other than MS, which may impact interpretation of study results or complicate identification or assessment of neurotoxicity;
• •31\. Any contraindications to lumbar puncture (LP), including but not limited to:
• •1. Known or suspected structural abnormalities of the lumbar vertebra that, in the opinion of the investigator, may interfere with the conduct of LP or increase the risk of the procedure to the subject;
• •2. Risk of increased or uncontrollable bleeding, including but not limited to vascular abnormalities or tumors at or around the LP site, coagulation cascade disorders, abnormal platelet function, or abnormal platelet counts;